<ul>
<li><em>收购后合并公司的收入产生商业资产和强大的产品及产品候选管道，旨在解决多种治疗领域，重点关注纤维化和炎症性疾病。</em></li>
<li><em>中国创新引擎为发现和早期开发靶向蛋白降解剂及降解剂 - 抗体结合物提供了成本高效的途径。</em></li>
<li><em>在美国加强了领导团队，同时在中国的运营存在支持未来的全球增长。</em></li>
</ul>
<p>圣地亚哥，2026 年 5 月 4 日（全球新闻稿）——Gyre Therapeutics, Inc.（“Gyre”，“Gyre Therapeutics” 或 “公司”）（纳斯达克：GYRE）是一家创新的商业阶段生物制药公司，致力于推动针对慢性疾病影响的器官系统的纤维化优先治疗，今天宣布完成对 Cullgen Inc.（Cullgen）的收购，Cullgen 是一家专注于靶向蛋白降解剂（TPD）和降解剂抗体结合物（DAC）疗法发现与开发的私营临床阶段生物制药公司，此次交易为全股票交易，估值约为 3 亿美元。</p>
<p>收购完成后，Cullgen 成为 Gyre 的全资子公司，Cullgen 的前首席执行官罗颖博士被任命为总裁兼首席执行官，并成为 Gyre 董事会成员。张平将继续担任 Gyre 董事会主席。新的合并实体将继续在纳斯达克资本市场上市，股票代码为 “GYRE”。</p>
<p>Gyre 的总裁兼首席执行官罗博士评论道：“我们渴望作为一家总部位于美国和中国的完全整合的生物制药公司向前迈进。通过这次合并，我们创建了一个不仅提供在中国市场上用于治疗肺纤维化的商业阶段产品 ETUARY®，而且还拥有从发现到第三阶段的全谱系产品管道，主要集中在纤维化和炎症性疾病上。这包括我们的主要产品候选 F351（hydronidone），用于治疗慢性乙型肝炎（CHB）引起的肝纤维化，以及强大的临床前和临床管道，包括 TPD 和 DAC。”</p>
<p>张先生，Gyre 的董事会主席评论道：“此次合并发生在 Gyre 一个激动人心的时刻，因为我们最近在 3 月份获得了中国国家药品监督管理局药品评审中心对 F351 新药申请的优先审评状态。我们还在探索 F351 在中国以外地区（包括美国）的开发扩展。此外，我们已完成对 52 周 ETUARY®尘肺症临床试验的入组，并在评估 ETUARY®在新适应症：放射性肺损伤（有或没有免疫检查点抑制剂相关肺炎）的第三阶段研究中招募了第一位患者，进一步增强了我们的晚期炎症产品组合。此外，我们相信，从 Cullgen 获得的几种有前景的降解剂和 DAC 所产生的创新发现引擎增强了我们的资产组合，并为 Gyre 提供了长期价值。”</p>
<p><strong>关于 Gyre 制药</strong></p>
<p>Gyre 制药有限公司是 Gyre Therapeutics, Inc.（“Gyre 制药”）的子公司，是一家商业阶段生物制药公司，致力于器官纤维化创新药物的研究、开发、生产和商业化。其旗舰产品 ETUARY®（吡非尼酮胶囊）是 2011 年在中华人民共和国（PRC）获得批准的首个特发性肺纤维化（IPF）治疗药物，并在过去几年中保持了显著的市场份额。此外，Gyre 制药的管道包括 F351（hydronidone），这是吡非尼酮的结构类似物，在 PRC 的 CHB 相关肝纤维化的关键第三阶段临床试验中显示出统计学显著的纤维化逆转。F351 于 2021 年 3 月获得国家药品监督管理局药品评审中心的突破性疗法认定。Gyre 制药还在开发针对帕金森病、放射性肺损伤（有或没有免疫相关肺炎）、慢性阻塞性肺病、肺动脉高压和急性肝衰竭/慢性肝衰竭的治疗。截至 2025 年 12 月 31 日，Gyre Therapeutics 拥有 Gyre 制药 69.7% 的股权。</p>
<p><strong>关于 Gyre Therapeutics</strong></p>
<p>Gyre Therapeutics 是一家总部位于加利福尼亚州圣地亚哥的生物制药公司，主要专注于 F351 的开发和商业化，针对肝纤维化，包括美国的代谢相关肝病（MASH），并且通过最近的收购，现在拥有一系列高度选择性的靶向蛋白降解剂产品候选，旨在有效且强效地消除患者体内的治疗相关蛋白，以及包括下一代降解剂 - 抗体结合物的临床前项目。</p>
<p>在中华人民共和国，Gyre Therapeutics 通过其对 Gyre 制药的控股权益推进广泛的产品管道，包括 ETUARY 的治疗扩展，以及 F573 和 F528 的开发项目。</p>
<p><strong>顾问和法律顾问</strong></p>
<p>Moelis &amp; Company LLC 担任 Gyre 董事会特别委员会的财务顾问，Gyre 的法律顾问为 Gibson, Dunn &amp; Crutcher LLP。</p>
<p>Mintz, Levin, Cohn, Ferris, Glovsky &amp; Popeo, P.C.担任 Cullgen 的法律顾问。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含根据 1995 年《私人证券诉讼改革法案》“安全港” 条款定义的 “前瞻性声明”，这些声明面临重大风险和不确定性，并基于估计和假设。除本新闻稿中包含的历史事实声明外，所有声明均为前瞻性声明，包括关于：合并实体未来运营的声明；合并实体的性质、战略和重点；合并实体任何产品候选者的发展和商业潜力及潜在利益；F351 在中国以外地区（包括美国）的潜在扩展；Cullgen 的降解剂和 DACs 增强 Gyre 资产组合的能力；以及收购的其他预期利益，包括成功整合 Gyre 和 Cullgen 的业务和运营的能力。在某些情况下，您可以通过 “可能”、“或许”、“将”、“目标”、“打算”、“应该”、“可以”、“会”、“期望”、“相信”、“设计”、“估计”、“预测”、“潜在”、“计划” 或这些术语的否定形式以及类似表达来识别前瞻性声明。这些声明反映了我们截至本新闻稿日期的计划、估计和期望。这些声明涉及已知和未知的风险、不确定性及其他因素，这些因素可能导致我们的实际结果与本新闻稿中表达或暗示的前瞻性声明存在重大差异。由于这些风险和不确定性，实际结果和事件的时间可能与预期的前瞻性声明存在重大差异，包括但不限于：收购所产生的意外成本、费用或支出；因收购的公告或完成而导致的潜在不利反应或商业关系变化；合并公司可能无法成功整合业务并及时或根本实现收购预期利益的风险；与 Gyre 和 Cullgen 的产品候选者相关的不确定性，以及与产品候选者的临床开发和监管批准相关的风险，包括临床试验的开始、招募和完成的潜在延迟；合并实体无法获得足够的额外资本以继续推进这些产品候选者及其临床前项目的风险；获得产品候选者成功临床结果的不确定性及可能由此产生的意外成本；未能从正在开发和预计将开发的产品候选者及临床前项目中实现任何价值的风险，考虑到成功将产品候选者推向市场所涉及的固有风险和困难；与未能实现收购的某些预期利益相关的风险，包括与未来财务和运营结果相关的风险。其他风险和因素在 Gyre 于 2026 年 3 月 13 日提交的截至 2025 年 12 月 31 日的年度报告的 “风险因素” 部分以及向证券交易委员会的其他文件中进行了说明。</p>
<p>Gyre 明确声明，除法律要求外，未有义务更新任何前瞻性声明，无论是由于新信息、未来事件还是其他原因。</p>
<p>联系方式：</p>
<p><strong>Gyre Therapeutics, Inc.</strong></p>
<p>Thomas Eastling，首席财务官</p>
<p>ir@gyretx.com</p>
<p><strong>投资者</strong></p>
<p>Chuck Padala</p>
<p>董事总经理，LifeSci Advisors</p>
<p>chuck@lifesciadvisors.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeE1qSTVNeU0zTlRnd01UQXpJekl3TVRrek16WT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeE1qSTVNeU0zTlRnd01UQXpJekl3TVRrek16WT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/OGM5ZjA3ZWUtOTlkMS00ZGYzLWJhMDMtMmExNWMzODA1YTlkLTEwMzA5MDktMjAyNi0wNS0wNC1lbg==/tiny/Gyre-Therapeutics-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/OGM5ZjA3ZWUtOTlkMS00ZGYzLWJhMDMtMmExNWMzODA1YTlkLTEwMzA5MDktMjAyNi0wNS0wNC1lbg==/tiny/Gyre-Therapeutics-Inc-.png"/></p>

GYRE

<p>Gyre Therapeutics 已完成对 Cullgen 的收购，此次交易为全股票交易，估值约为 3 亿美元，形成一家总部位于美国和中国的完全整合的生物制药公司。合并后的实体将专注于纤维化和炎症性疾病，利用商业资产和强大的产品管线，包括针对慢性乙型肝炎引起的肝纤维化的主要产品候选 F351。Dr. Ying Luo 被任命为首席执行官，公司将继续在纳斯达克以 GYRE 的股票代码交易</p>

<ul>
<li><em>Post-closing combined company has revenue-producing commercial asset and a robust pipeline of products and product candidates to address multiple therapeutic areas with a focus on fibrosis and inflammatory diseases.</em></li>
<li><em>China innovation engine provides cost-efficient vehicle for discovery and early-stage development of targeted protein degraders and degrader-antibody conjugates.</em></li>
<li><em>Strengthened leadership team in U.S., coupled with China operating presence to support future global growth.</em></li>
</ul>
<div class="lb-trans"><ul>
<li><em>收购后合并公司的收入产生商业资产和强大的产品及产品候选管道，旨在解决多种治疗领域，重点关注纤维化和炎症性疾病。</em></li>
<li><em>中国创新引擎为发现和早期开发靶向蛋白降解剂及降解剂 - 抗体结合物提供了成本高效的途径。</em></li>
<li><em>在美国加强了领导团队，同时在中国的运营存在支持未来的全球增长。</em></li>
</ul>
</div><p>SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (“Gyre”, “Gyre Therapeutics” or the “Company”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic diseases, today announced the closing of its acquisition of Cullgen Inc. (Cullgen), a privately-held, clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degrader (TPD) and degrader antibody conjugate (DAC) therapies, in an all-stock transaction valued at approximately $300 million.</p>
<div class="lb-trans"><p>圣地亚哥，2026 年 5 月 4 日（全球新闻稿）——Gyre Therapeutics, Inc.（“Gyre”，“Gyre Therapeutics” 或 “公司”）（纳斯达克：GYRE）是一家创新的商业阶段生物制药公司，致力于推动针对慢性疾病影响的器官系统的纤维化优先治疗，今天宣布完成对 Cullgen Inc.（Cullgen）的收购，Cullgen 是一家专注于靶向蛋白降解剂（TPD）和降解剂抗体结合物（DAC）疗法发现与开发的私营临床阶段生物制药公司，此次交易为全股票交易，估值约为 3 亿美元。</p>
</div><p>Following the closing of the acquisition, Cullgen became a wholly owned subsidiary of Gyre, and the former Chief Executive Officer of Cullgen, Dr. Ying Luo, was appointed President and Chief Executive Officer and as a member of the Gyre Board of Directors. Ping Zhang will continue at Gyre as Chairman of the Board of Directors. The new combined entity will continue to be listed on the Nasdaq Capital Market under the ticker “GYRE”.</p>
<div class="lb-trans"><p>收购完成后，Cullgen 成为 Gyre 的全资子公司，Cullgen 的前首席执行官罗颖博士被任命为总裁兼首席执行官，并成为 Gyre 董事会成员。张平将继续担任 Gyre 董事会主席。新的合并实体将继续在纳斯达克资本市场上市，股票代码为 “GYRE”。</p>
</div><p>Dr. Luo, President and Chief Executive Officer of Gyre, commented, “We are eager to move forward as a U.S.- and China-based fully integrated biopharmaceutical company <em>.</em> Through this combination, we have created an entity that not only offers a commercial-stage product with ETUARY®, on the market in China for the treatment of lung fibrosis, but also a full-spectrum pipeline of products from discovery to Phase 3, primarily focused on fibrosis and inflammatory diseases. This includes our lead product candidate, F351 (hydronidone) for the treatment of chronic hepatitis B (CHB)-induced liver fibrosis, as well as a strong preclinical and clinical pipeline, including TPDs and DACs.”</p>
<div class="lb-trans"><p>Gyre 的总裁兼首席执行官罗博士评论道：“我们渴望作为一家总部位于美国和中国的完全整合的生物制药公司向前迈进。通过这次合并，我们创建了一个不仅提供在中国市场上用于治疗肺纤维化的商业阶段产品 ETUARY®，而且还拥有从发现到第三阶段的全谱系产品管道，主要集中在纤维化和炎症性疾病上。这包括我们的主要产品候选 F351（hydronidone），用于治疗慢性乙型肝炎（CHB）引起的肝纤维化，以及强大的临床前和临床管道，包括 TPD 和 DAC。”</p>
</div><p>Mr. Zhang, Chairman of Gyre, commented, “This combination occurs at an exciting time for Gyre as we recently received priority review status from the Center for Drug Evaluation of China’s National Medical Products Administration for the F351 NDA in March. We are also exploring the expansion of F351’s development in ex-China territories including the U.S. In addition, we have completed enrollment in our 52-week Phase 3 ETUARY® trial for pneumoconiosis, and have also enrolled the first patient in a Phase 3 study evaluating ETUARY® in a new indication: radiation-induced lung injury with or without immune checkpoint inhibitor-related pneumonitis, further strengthening our late-stage inflammatory portfolio. Additionally, we believe the innovative discovery engine that has produced several promising degraders and DACs acquired from Cullgen strengthens our asset portfolio and provides long-term value to Gyre.”</p>
<div class="lb-trans"><p>张先生，Gyre 的董事会主席评论道：“此次合并发生在 Gyre 一个激动人心的时刻，因为我们最近在 3 月份获得了中国国家药品监督管理局药品评审中心对 F351 新药申请的优先审评状态。我们还在探索 F351 在中国以外地区（包括美国）的开发扩展。此外，我们已完成对 52 周 ETUARY®尘肺症临床试验的入组，并在评估 ETUARY®在新适应症：放射性肺损伤（有或没有免疫检查点抑制剂相关肺炎）的第三阶段研究中招募了第一位患者，进一步增强了我们的晚期炎症产品组合。此外，我们相信，从 Cullgen 获得的几种有前景的降解剂和 DAC 所产生的创新发现引擎增强了我们的资产组合，并为 Gyre 提供了长期价值。”</p>
</div><p><strong>About Gyre Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>关于 Gyre 制药</strong></p>
</div><p>Gyre Pharmaceuticals Co., Ltd., a subsidiary of Gyre Therapeutics, Inc. (“Gyre Pharmaceuticals”), is a commercial-stage biopharmaceutical company committed to the research, development, manufacturing and commercialization of innovative drugs for organ fibrosis. Its flagship product, ETUARY® (pirfenidone capsule), was the first approved treatment for IPF in the People’s Republic of China (PRC) in 2011 and has maintained a prominent market share over the past several years. In addition, Gyre Pharmaceuticals’ pipeline includes F351 (hydronidone), a structural analogue of pirfenidone, which demonstrated statistically significant fibrosis regression after 52 weeks of treatment in a pivotal Phase 3 clinical trial in CHB-associated liver fibrosis in the PRC. F351 received Breakthrough Therapy designation by the CDE of the NMPA in March 2021. Gyre Pharmaceuticals is also developing treatments for PD, RILI with or without immune-related pneumonitis, COPD, PAH and ALF/ACLF. As of December 31, 2025, Gyre Therapeutics owns a 69.7% equity interest in Gyre Pharmaceuticals.</p>
<div class="lb-trans"><p>Gyre 制药有限公司是 Gyre Therapeutics, Inc.（“Gyre 制药”）的子公司，是一家商业阶段生物制药公司，致力于器官纤维化创新药物的研究、开发、生产和商业化。其旗舰产品 ETUARY®（吡非尼酮胶囊）是 2011 年在中华人民共和国（PRC）获得批准的首个特发性肺纤维化（IPF）治疗药物，并在过去几年中保持了显著的市场份额。此外，Gyre 制药的管道包括 F351（hydronidone），这是吡非尼酮的结构类似物，在 PRC 的 CHB 相关肝纤维化的关键第三阶段临床试验中显示出统计学显著的纤维化逆转。F351 于 2021 年 3 月获得国家药品监督管理局药品评审中心的突破性疗法认定。Gyre 制药还在开发针对帕金森病、放射性肺损伤（有或没有免疫相关肺炎）、慢性阻塞性肺病、肺动脉高压和急性肝衰竭/慢性肝衰竭的治疗。截至 2025 年 12 月 31 日，Gyre Therapeutics 拥有 Gyre 制药 69.7% 的股权。</p>
</div><p><strong>About Gyre Therapeutics</strong></p>
<div class="lb-trans"><p><strong>关于 Gyre Therapeutics</strong></p>
</div><p>Gyre Therapeutics is a biopharmaceutical company headquartered in San Diego, CA, primarily focused on the development and commercialization of F351 for liver fibrosis including MASH in the U.S., and, with its recent acquisition, now has a portfolio of highly selective targeted protein degrader product candidates designed to potently and efficiently eliminate therapeutically relevant proteins in patients, as well as preclinical programs including next-generation degrader-antibody conjugates.</p>
<div class="lb-trans"><p>Gyre Therapeutics 是一家总部位于加利福尼亚州圣地亚哥的生物制药公司，主要专注于 F351 的开发和商业化，针对肝纤维化，包括美国的代谢相关肝病（MASH），并且通过最近的收购，现在拥有一系列高度选择性的靶向蛋白降解剂产品候选，旨在有效且强效地消除患者体内的治疗相关蛋白，以及包括下一代降解剂 - 抗体结合物的临床前项目。</p>
</div><p>In the PRC, Gyre Therapeutics is advancing a broad pipeline through its controlling interest in Gyre Pharmaceuticals, including therapeutic expansions of ETUARY, and development programs for F573, and F528.</p>
<div class="lb-trans"><p>在中华人民共和国，Gyre Therapeutics 通过其对 Gyre 制药的控股权益推进广泛的产品管道，包括 ETUARY 的治疗扩展，以及 F573 和 F528 的开发项目。</p>
</div><p><strong>Advisory and Legal Counsel</strong></p>
<div class="lb-trans"><p><strong>顾问和法律顾问</strong></p>
</div><p>Moelis &amp; Company LLC is acting as financial advisor to the special committee to Gyre’s Board of Directors, and Gyre’s legal counsel is Gibson, Dunn &amp; Crutcher LLP.</p>
<div class="lb-trans"><p>Moelis &amp; Company LLC 担任 Gyre 董事会特别委员会的财务顾问，Gyre 的法律顾问为 Gibson, Dunn &amp; Crutcher LLP。</p>
</div><p>Mintz, Levin, Cohn, Ferris, Glovsky &amp; Popeo, P.C. is serving as legal counsel to Cullgen.</p>
<div class="lb-trans"><p>Mintz, Levin, Cohn, Ferris, Glovsky &amp; Popeo, P.C.担任 Cullgen 的法律顾问。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, are forward-looking statements, including statements concerning: the future operations of the combined entity; the nature, strategy and focus of the combined entity; the development and commercial potential and potential benefits of any product candidates of the combined entity; potential expansion of F351 in ex-China territories including the U.S.; the ability of Cullgen’s degraders and DACs to strengthen Gyre’s asset portfolio; and the additional expected benefits of the acquisition, including its ability to successfully integrate the businesses and operations of Gyre and Cullgen. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “plan” or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements reflect our plans, estimates, and expectations, as of the date of this press release. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this press release. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation: unexpected costs, charges or expenses resulting from the acquisition; potential adverse reactions or changes to business relationships resulting from the announcement or completion of the acquisition; the risk that the combined company may not be able to successfully integrate the businesses and realize the expected benefits of the acquisition in a timely manner or at all; the uncertainties associated with Gyre’s and Cullgen’s product candidates, as well as risks associated with the clinical development and regulatory approval of product candidates, including potential delays in the commencement, enrollment and completion of clinical trials; risks related to the inability of the combined entity to obtain sufficient additional capital to continue to advance these product candidates and its preclinical programs; uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom; risks related to the failure to realize any value from product candidates and preclinical programs being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; risks associated with the possible failure to realize certain anticipated benefits of the acquisition, including with respect to future financial and operating results. Additional risks and factors are identified under “Risk Factors” in Gyre’s Annual Report on Form 10-K for the year ended December 31, 2025 filed on March 13, 2026, and in other filings with the Securities and Exchange Commission.</p>
<div class="lb-trans"><p>本新闻稿包含根据 1995 年《私人证券诉讼改革法案》“安全港” 条款定义的 “前瞻性声明”，这些声明面临重大风险和不确定性，并基于估计和假设。除本新闻稿中包含的历史事实声明外，所有声明均为前瞻性声明，包括关于：合并实体未来运营的声明；合并实体的性质、战略和重点；合并实体任何产品候选者的发展和商业潜力及潜在利益；F351 在中国以外地区（包括美国）的潜在扩展；Cullgen 的降解剂和 DACs 增强 Gyre 资产组合的能力；以及收购的其他预期利益，包括成功整合 Gyre 和 Cullgen 的业务和运营的能力。在某些情况下，您可以通过 “可能”、“或许”、“将”、“目标”、“打算”、“应该”、“可以”、“会”、“期望”、“相信”、“设计”、“估计”、“预测”、“潜在”、“计划” 或这些术语的否定形式以及类似表达来识别前瞻性声明。这些声明反映了我们截至本新闻稿日期的计划、估计和期望。这些声明涉及已知和未知的风险、不确定性及其他因素，这些因素可能导致我们的实际结果与本新闻稿中表达或暗示的前瞻性声明存在重大差异。由于这些风险和不确定性，实际结果和事件的时间可能与预期的前瞻性声明存在重大差异，包括但不限于：收购所产生的意外成本、费用或支出；因收购的公告或完成而导致的潜在不利反应或商业关系变化；合并公司可能无法成功整合业务并及时或根本实现收购预期利益的风险；与 Gyre 和 Cullgen 的产品候选者相关的不确定性，以及与产品候选者的临床开发和监管批准相关的风险，包括临床试验的开始、招募和完成的潜在延迟；合并实体无法获得足够的额外资本以继续推进这些产品候选者及其临床前项目的风险；获得产品候选者成功临床结果的不确定性及可能由此产生的意外成本；未能从正在开发和预计将开发的产品候选者及临床前项目中实现任何价值的风险，考虑到成功将产品候选者推向市场所涉及的固有风险和困难；与未能实现收购的某些预期利益相关的风险，包括与未来财务和运营结果相关的风险。其他风险和因素在 Gyre 于 2026 年 3 月 13 日提交的截至 2025 年 12 月 31 日的年度报告的 “风险因素” 部分以及向证券交易委员会的其他文件中进行了说明。</p>
</div><p>Gyre expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.</p>
<div class="lb-trans"><p>Gyre 明确声明，除法律要求外，未有义务更新任何前瞻性声明，无论是由于新信息、未来事件还是其他原因。</p>
</div><p>CONTACTS:</p>
<div class="lb-trans"><p>联系方式：</p>
</div><p><strong>Gyre Therapeutics, Inc.</strong></p>
<div class="lb-trans"><p><strong>Gyre Therapeutics, Inc.</strong></p>
</div><p>Thomas Eastling, CFO</p>
<div class="lb-trans"><p>Thomas Eastling，首席财务官</p>
</div><p>ir@gyretx.com</p>
<div class="lb-trans"><p>ir@gyretx.com</p>
</div><p><strong>Investors</strong></p>
<div class="lb-trans"><p><strong>投资者</strong></p>
</div><p>Chuck Padala</p>
<div class="lb-trans"><p>Chuck Padala</p>
</div><p>Managing Director, LifeSci Advisors</p>
<div class="lb-trans"><p>董事总经理，LifeSci Advisors</p>
</div><p>chuck@lifesciadvisors.com</p>
<div class="lb-trans"><p>chuck@lifesciadvisors.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeE1qSTVNeU0zTlRnd01UQXpJekl3TVRrek16WT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTcxMjI5MyM3NTgwMTAzIzIwMTkzMzY="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/OGM5ZjA3ZWUtOTlkMS00ZGYzLWJhMDMtMmExNWMzODA1YTlkLTEwMzA5MDktMjAyNi0wNS0wNC1lbg==/tiny/Gyre-Therapeutics-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/OGM5ZjA3ZWUtOTlkMS00ZGYzLWJhMDMtMmExNWMzODA1YTlkLTEwMzA5MDktMjAyNi0wNS0wNC1lbg==/tiny/Gyre-Therapeutics-Inc-.png"/></p>

Gyre Therapeutics 完成了对 Cullgen 的收购，成立了一家总部设在美国和中国的全方位整合生物制药公司 | GYRE 股票新闻